Category Archives: Maryland Stem Cells

Various in vitro cell culture assays have been used for decades to evaluate disease pathology and uncover potential therapeutic treatments. Despite many successes with these models, they have critical shortcomings. Growing evidence suggests that models providing more predictive and translational observations are desperately needed. Researchers are now moving from reductionist, 2D monoculture assay models to more complex 3D cell models, such as organoids and induced pluripotent stem cell (iPSC) cultures, in order to better evaluate the dynamic interactions between cells in an environment more closely emulating that of the in vivo milieu, and to assess patient-specific phenotypic effects following drug treatment. Effective, well-characterized, advanced cell models hold promise for improving our understanding of disease pathology and progression, and are critical for the identification of novel therapeutic targets.

During this roundtable webinar, the speakers will:

This webinar will last for approximately 60 minutes.

STEMCELL TechnologiesCambridge, UK

Dr. Simmini is an R&D scientist in the gastrointestinal biology group at STEMCELL Technologies. His group focuses on developing products that support the generation of 3D gastrointestinal organoid cultures both from human primary tissue and human induced pluripotent stem cells. Prior to joining STEMCELL Technologies in 2016, he obtained his Ph.D. in stem cells, developmental biology, and cancer at the University of Utrecht in The Netherlands. During that time, he conducted research with the group of Jacqueline Deschamps at the Hubrecht Institute in Utrecht, where he investigated the molecular mechanisms controlled by transcription factor CDX2 in adult mouse intestinal stem cells and during embryonic development. In 2015, he began postdoctoral research, joining the group of Jan Paul Medema and Louis Vermeulen at the Amsterdam Medical Centre in Amsterdam, where he investigated mechanisms regulating intestinal stem cell proliferation and differentiation in colorectal cancer. He is currently involved in several Horizon 2020 European Research Council projects in different roles: researcher within the INTENS (INtestinal Tissue ENgineering Solution) consortium; partner in the SINERGIA (Advanced technologieS for drug dIscovery and precisioN mEdicine: in vitRo modellinG human physiology and diseAse) project; and supervisor and member of the executive board of the Organovir-ETN (Organoids for Virus Research-European Training Network) grant.

Wellcome Sanger InstituteCambridge, UK

As a staff scientist at the Wellcome Sanger Institute, Dr.Hale undertakes basic research projects into hostbacterial interactions while also teaching relevant skills to students and visiting scientists. Her projects include growing and differentiating human induced pluripotent stem cells to either a macrophage-like lineage or as intestinal 3D organoids, then utilizing them to investigate pathogen interactions. The main techniques used are flow cytometry, confocal imaging, high-throughput Cellomics assays, Luminex cytokine assays, and cell culture. The pathogens have varied over the years, but have included Salmonella, Klebsiella, enteropathogenic Escherichia coli (EPEC), Chlamydia, and Leishmania.

UK Dementia Research InstituteCambridge, UK

Dr. Avezov received his Ph.D. in cell research and immunology from the George S. Wise Faculty of Life Sciences at Tel Aviv University in 2010. He conducted his postdoctoral work at the University of Cambridge Wellcome-MRC Institute of Metabolic Science and the Cambridge Institute for Medical Research until 2017 with David Ron, FRS. Quantitative cell biology in the context of human disease has been at the core of Dr. Avezovs research. Working at the interface of biomedical research, physics, and mathematical sciences, he developed the cross-disciplinary expertise for probing intracellular chemical and physical processes in real time. This enabled discoveries of unexpected features of the endoplasmic reticulum (ER), such as an active ER luminal transport mechanism. These findings provide insights into the roles of the ER and its morpho-regulation in neuronal (patho)physiology. Dr. Avezov is currently a UK Dementia Research Institute Group Leader running an interdisciplinary program that seeks to understand early contributions of fundamental cellular processes ranging from ER transport to neurodegeneration.

Science/AAASWashington, D.C.

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Original post:
Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine

ByKristin Hanson

This article was originally published on Nov. 8 on giving.jhu.edu

Between 2001 and the beginning of 2018, more than 1,500 U.S. military service members lost limbs in the line of duty. Although technology has improved the prosthetic devices these people can use, a stubborn obstacle remains: the fragility of human skin.

"Skin was never meant to hold this kind of pressure," says Lee Childers, the senior scientist for the Extremity Trauma and Amputation Center of Excellence at Brooke Army Medical Center in San Antonio, Texas.

"Think about it like a blister on your foot. It's painful, but you can still get by," he continues. "In an amputation, it's a blister on your residual limb. You can't use your prosthesis until the blister is completely healed. If it's your leg [that is affected], you can't walk for two or three weeks. Think about how that would impact your life."

What if there were a way to make the skin at an amputation site tougher, like the palm of your hand or the sole of your foot? Luis Garza, an associate professor of dermatology at Johns Hopkins and leader of the Veteran Amputee Skin Regeneration Program, is developing a cell therapy that could enable prosthetics wearers to use their devices longer.

"This is an example of personalized medicine," Garza says. "We're taking each person's own cells, growing them up, and inserting them back in."

Garza's postdoctoral research focused on skin stem cells. In 2009, he and his department chair, Sewon Kang, began having conversations about how that work could help the increasing numbers of veterans coming back from war with amputations. Garza and his team received grants from the U.S. Department of Defense, National Institutes of Health, and Maryland Stem Cell Fund that have moved the program forward in the past decade.

Garza's team spent the summer of 2019 testing "normal" subjectsthose without amputationsto perfect the procedure, including the dose, content, method, and frequency of the injections. During one appointment, members of Garza's team took biopsies of skin from a subject's scalp and sole. The cells went to a lab where they were grown under an FDA-approved protocol and passed through quality control tests.

In a second appointment, subjects completed a questionnaire and underwent baseline measurements of their skin's thickness and strength. Garza's team then injected a site on the subjects' skin with the stem cells grown from their cells in the lab.

Image caption: Luis Garza, associate professor of dermatology at Johns Hopkins, leads the Veteran Amputee Skin Regeneration Program.

"We're hoping that these stem cell populations will engraft in the new skin," Garza says.

The subjects returned to Hopkins several months later to go through the questionnaire and measurements once more, and Garza's team documented changes.

Confident in the results they gleaned from the normal subjects, Garza's team enrolled its first subject with an amputation in August. Moving from the normal population to the amputation-affected population quickly unearthed some aspects of the therapy Garza didn't anticipate.

"When we talked with him, he said 'I don't want to mess with my one remaining footdo you have to take skin from there?' And we said, 'Actually, no, we could do your palm,'" Garza says.

His team then tested the biopsy and growth of palm cells from subjects in the normal population. "We're moving away from having our product informed purely by biology to letting our therapy development be shaped by the user."

Although federal grants have supported much of the program's progress, private philanthropy has played a role, too. Corporations like Northrop Grumman, foundations like the Alliance for Veteran Support, and grateful patients with and without ties to the armed forces have contributed nearly $300,000. Those gifts have enabled the program to persevere through gaps between federal grants.

Private funds will be increasingly important as the project enters its next phase: extension to military medical centers around the country. Garza's team must prove that the safeguards to protect cells on their round-trip voyage from a test site to Hopkins are effective. They also must secure approval by local institutional review boards for clinical studies.

"Soldiers are used to getting orders, but you can't order someone to be part of a [medical] study," Garza says. "There are hard medical ethics questions around how to make this open to them but ensure they don't feel obligated. We've been working on that for a year, and we probably have another six months or so to go."

Childers stands ready for whenever the program's extension is a go. He will lead the study at Brooke Army Medical Center and feels motivated by the prospect of helping many of the veterans he works with every day.

"We do everything we can to serve those who serve us. This can enable people to return to duty and be redeployed if they choose," he says. "This is game-changing technology that will have an impact for our service members, but also others who live with amputation."

That population includes the hundreds of thousands of Americans who've undergone amputations for complications of diabetes, who must use a wheelchair, or who wear ankle or foot orthoses for help with walking, among others.

"Having the ability to transform skin anywhere you want to target on the body will have gigantic implications across the entire spectrum of our society in many ways," Childers says.

There's a lot of work to be done before such benefits reach the public, Garza cautions. With continued support from donors and the military community, though, he's optimistic about the program's future.

"The challenges are pretty big, but I think within five years, it could happen," he says. "That's the hope."

Disclaimer: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of the Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force and Department of Defense or the U.S. Government.

Continue reading here:
Serving those who serve - The Hub at Johns Hopkins

His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

POWAY, Calif. (PRWEB) November 05, 2019

Ole, a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. He was lame and stiff and had difficulty with stairs and jumping. Though his energy level and his willingness to play were normal, it was clear that he was in pain.

Oles owner took him to veterinary surgeon Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center in San Diego, California. Dr. Mullen is an experienced VetStem user and has provided VetStem Cell Therapy services for over sixty patients. Upon examination, Dr. Mullen diagnosed Ole with severe osteoarthritis in his hips as a result of hip dysplasia. In patients with joint dysplasia, the affected joint is malformed causing the bone to rub irregularly, which can eventually lead to osteoarthritis. Ole was also diagnosed with osteoarthritis in his lower, or lumbar, spine. It was apparent that these issues were causing Ole discomfort.

In an effort to provide relief, Dr. Mullen recommended Ole receive VetStem Cell Therapy. Adipose-, or fat-derived, stem cell therapy is used by veterinarians to treat osteoarthritis and soft tissue injuries. VetStem Cell Therapy utilizes a patients natural healing cells which may reduce inflammation, block pain, and regenerate damaged joint tissues.

To begin the process, Dr. Mullen extracted fat from Oles abdomen in a minimally invasive anesthetic procedure. The fat was delivered to the VetStem laboratory in Poway, California where it was received and aseptically processed by trained VetStem laboratory technicians. Oles stem cells were extracted and concentrated from his fat tissue and dosed out into an injection that was delivered back to Dr. Mullen. Within 48 hours of the initial fat collection, Ole received one intravenous injection of his own stem cells.

As a follow up to his first injection, Ole received additional stem cell injections approximately two months later. This time he received one injection into each hip, injections along the muscles in his back, as well as an intravenous injection.

In a 90-day post stem cell therapy evaluation (approximately 90 days after the first treatment), Oles owner reported that he was no longer stiff or painful. She also noticed an improvement in his ability to go up and down the stairs, walk, and jump. His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

Dr. Mullens findings were similar at the 90-day examination. She stated, He is doing great! He runs around [the owners] acreage every day with no overt lameness and no signs of painhes strongly ambulatory with a bouncy gait.

Like Ole, many dogs suffer from osteoarthritis and unfortunately, treatment options are somewhat limited. For these patients, VetStem Cell Therapy may be an option. According to owners and veterinarians, greater than 80% of dogs showed an improved quality of life after receiving VetStem Cell Therapy for orthopedic conditions. Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. In a peer-reviewed study of dogs with chronic osteoarthritis of the hip, it was found that stem cells reduced lameness and pain.

About Holly Mullen, DVM, DACVSDr. Mullen received her DVM from Virginia-Maryland Regional College of Veterinary Medicine in 1985. She completed a small animal medicine and surgery internship as well as a residency in small animal surgery at the Animal Medical Center in New York City. In 1990, she became a board-certified veterinary surgeon. Dr. Mullen has been providing VetStem Cell Therapy for over a decade.

About VetStem Biopharma, Inc.VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Share article on social media or email:

Here is the original post:
VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web

TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd.(NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of BL-8040 in combination with an anti PD-1 and chemotherapy. The results, summarized in a poster entitled, "Combination of BL-8040, anti PD-1 and chemotherapy significantly reduced pancreatic tumor growth and changed the balance between CD4+/FOXP3+ cells and CD8+ cells in the tumor", will be presented on November 8, 2019 at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland.

"The results seen in this preclinical pancreatic cancer study support our hypothesis that the triple combination of BL-8040, anti-PD-1 and chemotherapy helps combat this difficult to treat cancer," said Philip Serlin, Chief Executive Officer of BioLineRx. "These preclinical data from the triple combination study support the mechanism of action of BL-8040 demonstrated in earlier clinical data from the dual combination of BL-8040 and pembrolizumab, showing a reduction in immuno-suppressive cells, accompanied by an increase in activated effector CD8+ T cells. We believe the ability of BL-8040 to modulate the tumor microenvironment allows for better activation of immune effector cells when combined with chemotherapy and immunotherapy. We are very hopeful that this anti-tumor activity will be confirmed in humans as we eagerly await results from the triple combination arm of our COMBAT/KEYNOTE-202 Phase 2 study of BL-8040, KEYTRUDA and chemotherapy in metastatic pancreatic cancer, which we expect to report by year end."

About the Pre-Clinical Study

The pre-clinical study assessed the effects of BL-8040, anti-PD-1 and chemotherapy (Irinotecan, Fluorouracil and Leucovorin), both alone and in various combinations, on tumor growth and immune cell constitution in a mouse model for pancreatic cancer.

Key findings include:

About BL-8040

BL-8040 is a short synthetic peptide that functions as a high-affinity best-in-class antagonist for CXCR4, a chemokine receptor over-expressed in many human cancers. CXCR4 has been shown to be correlated with poor prognosis, and plays a key role in tumor growth, invasion, angiogenesis, metastasis and therapeutic resistance. CXCR4 is also directly involved in the homing and retention of hematopoietic stem cells (HSCs) and various hematological malignant cells in the bone marrow.

In a number of clinical and preclinical studies, BL-8040 has shown a critical role in immune cell trafficking, tumor infiltration by immune effector T cells and reduction in immunosuppressive cells within the tumor niche, turning "cold" tumors, such as pancreatic cancer, into "hot" tumors (i.e., sensitizing them to immune check point inhibitors). BL-8040-mediated inhibition of the CXCR4-CXCL12 (SDF-1) axis has also shown robust mobilization of HSCs for transplantation in hematological malignancies.

BL-8040 was licensed by BioLineRx from Biokine Therapeutics and was previously developed under the name BKT-140.

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on multiple oncology indications. The Company's lead program, BL-8040, is a cancer therapy platform currently being evaluated in a Phase 2a study in pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD. BL-8040 is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous hematopoietic cell transplantation. In addition, the Company has an ongoing collaboration agreement with Genentech, a member of the Roche Group, evaluating BL-8040 in combination with Genentech's atezolizumab in two Phase 1b/2 solid tumor studies.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being evaluated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2019. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthyLifeSci Advisors, LLC+1-212-915-2564tim@lifesciadvisors.com

Tsipi HaitovskyPublic Relations+972-52-598-9892tsipihai5@gmail.com

View original content:http://www.prnewswire.com/news-releases/biolinerx-presents-preclinical-data-from-triple-combination-of-bl-8040-anti-pd-1-and-chemotherapy-demonstrating-significant-reduction-in-pancreatic-tumor-growth-and-favorable-changes-in-tumor-microenvironment-300951519.html

SOURCE BioLineRx Ltd.

Read the rest here:
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic...

Applied Therapeutics Inc. (NASDAQ:APLT) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Table 1 showcases the gross revenue, earnings per share and valuation of Applied Therapeutics Inc. and Neuralstem Inc.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Insider & Institutional Ownership

The shares of both Applied Therapeutics Inc. and Neuralstem Inc. are owned by institutional investors at 0% and 4.9% respectively. On the other hand, insiders owned about 1% of Neuralstem Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Applied Therapeutics Inc. has stronger performance than Neuralstem Inc.

Summary

Applied Therapeutics Inc. beats Neuralstem Inc. on 6 of the 9 factors.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post:
Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly

Synthetic Biologics Inc. (NYSEAMERICAN:SYN) and Asterias Biotherapeutics Inc. (:), both competing one another are Biotechnology companies. We will contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation & Earnings

Table 1 showcases the gross revenue, earnings per share and valuation of Synthetic Biologics Inc. and Asterias Biotherapeutics Inc.

Profitability

Table 2 shows us Synthetic Biologics Inc. and Asterias Biotherapeutics Inc.s net margins, return on equity and return on assets.

Institutional & Insider Ownership

The shares of both Synthetic Biologics Inc. and Asterias Biotherapeutics Inc. are owned by institutional investors at 13.3% and 13.75% respectively. Synthetic Biologics Inc.s share owned by insiders are 0.1%. Comparatively, Asterias Biotherapeutics Inc. has 40.53% of its share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Summary

On 4 of the 7 factors Synthetic Biologics Inc. beats Asterias Biotherapeutics Inc.

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. The company also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Reviewing Synthetic Biologics Inc. (SYN)'s and Asterias Biotherapeutics Inc. (:)'s results - FinanceMercury

Neuralstem Inc. (NASDAQ:CUR) and Allakos Inc. (NASDAQ:ALLK), both competing one another are Biotechnology companies. We will compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Table 1 demonstrates Neuralstem Inc. and Allakos Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Neuralstem Inc. and Allakos Inc.s net margins, return on equity and return on assets.

Liquidity

The Current Ratio of Neuralstem Inc. is 3.8 while its Quick Ratio stands at 3.8. The Current Ratio of rival Allakos Inc. is 20.5 and its Quick Ratio is has 20.5. Allakos Inc. is better equipped to clear short and long-term obligations than Neuralstem Inc.

Institutional & Insider Ownership

The shares of both Neuralstem Inc. and Allakos Inc. are owned by institutional investors at 4.9% and 97.4% respectively. Insiders held 1% of Neuralstem Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Neuralstem Inc. was more bearish than Allakos Inc.

Summary

Allakos Inc. beats Neuralstem Inc. on 7 of the 9 factors.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Visit link:
Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) - MS Wkly

Intrexon (NASDAQ:XON) and US Stem Cell (OTCMKTS:USRM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Intrexon and US Stem Cell, as provided by MarketBeat.com.

Intrexon currently has a consensus price target of $19.67, indicating a potential upside of 238.79%. Given Intrexons higher probable upside, research analysts clearly believe Intrexon is more favorable than US Stem Cell.

Valuation and Earnings

This table compares Intrexon and US Stem Cells revenue, earnings per share (EPS) and valuation.

US Stem Cell has lower revenue, but higher earnings than Intrexon.

Risk & Volatility

Intrexon has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.02, meaning that its share price is 402% more volatile than the S&P 500.

Insider & Institutional Ownership

75.7% of Intrexon shares are owned by institutional investors. 44.0% of Intrexon shares are owned by insiders. Comparatively, 16.7% of US Stem Cell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Intrexon and US Stem Cells net margins, return on equity and return on assets.

Summary

Intrexon beats US Stem Cell on 7 of the 11 factors compared between the two stocks.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:
Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) - Riverton Roll

US Stem Cell (OTCMKTS:USRM) and Intrexon (NASDAQ:XON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares US Stem Cell and Intrexons revenue, earnings per share and valuation.

US Stem Cell has higher earnings, but lower revenue than Intrexon.

Risk & Volatility

US Stem Cell has a beta of 5.01, indicating that its share price is 401% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.

Institutional and Insider Ownership

75.7% of Intrexon shares are owned by institutional investors. 16.7% of US Stem Cell shares are owned by insiders. Comparatively, 44.0% of Intrexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares US Stem Cell and Intrexons net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for US Stem Cell and Intrexon, as reported by MarketBeat.com.

Intrexon has a consensus price target of $19.67, suggesting a potential upside of 213.16%. Given Intrexons higher probable upside, analysts plainly believe Intrexon is more favorable than US Stem Cell.

Summary

Intrexon beats US Stem Cell on 7 of the 11 factors compared between the two stocks.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Excerpt from:
Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) - TechNewsObserver

Intrexon (NASDAQ:XON) and US Stem Cell (OTCMKTS:USRM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility and Risk

Intrexon has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.02, suggesting that its share price is 402% more volatile than the S&P 500.

75.7% of Intrexon shares are owned by institutional investors. 44.0% of Intrexon shares are owned by insiders. Comparatively, 16.7% of US Stem Cell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Intrexon and US Stem Cell, as reported by MarketBeat.

Intrexon currently has a consensus target price of $19.67, indicating a potential upside of 211.18%. Given Intrexons higher probable upside, analysts clearly believe Intrexon is more favorable than US Stem Cell.

Profitability

This table compares Intrexon and US Stem Cells net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Intrexon and US Stem Cells revenue, earnings per share and valuation.

US Stem Cell has lower revenue, but higher earnings than Intrexon.

Summary

Intrexon beats US Stem Cell on 7 of the 11 factors compared between the two stocks.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Go here to see the original:
Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) - Mayfield Recorder